Diabetic nephropathy screening

Revision as of 20:36, 13 June 2018 by Ahmed Younes (talk | contribs) (Overview)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Diabetic nephropathy Microchapters


Patient Information


Historical Perspective




Differentiating Diabetic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic nephropathy screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Diabetic nephropathy screening

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic nephropathy screening

CDC on Diabetic nephropathy screening

Diabetic nephropathy screening in the news

Blogs on Diabetic nephropathy screening

Directions to Hospitals Treating Diabetic nephropathy

Risk calculators and risk factors for Diabetic nephropathy screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2], Dima Nimri, M.D. [3]


Microalbuminuria is an excellent tool for the early detection of diabetic nephropathy.


  • Screening for nephropathy in diabetes should begin at the time of diagnosis of type II diabetes mellitus[1] and after 5 years of the diagnosis of type I diabetes mellitus.[2]
  • Screening for albuminuria is done with a routine dipstick urinalysis. However, routine dipsticks do not rule out microalbuminuria. Hence, if the test is positive, a 24-hour urine sample for quantifying the amount of protein should be done and if the test is negative, a radioimmunoassay for albumin should be done and repeated every year if the initial result is negative.
  • The albumin to creatinine ratio should also be measured in a morning urine sample, a 24-hour or an overnight sample.
    • In the case of an abnormal urine albumin to creatinine ratio (more than 30 mg/ g Cr), test should be repeated once or twice over a period of few months for consistency of the results.
  • Estimated GFR (eGFR) is often calculated at the time of screening to document and/or stage chronic kidney disease (CKD).
  • If retinopathy is present along with albuminuria, the albuminuria is highly attributed to diabetic nephropathy.[1][2]
  • New genetic markers are being studied for diabetic nephropathy. These markers are being determined in order to facilitate an early identification and management of patients at a high risk of developing diabetic nephropathy.[2]


  1. 1.0 1.1 Remuzzi G, Schieppati A, Ruggenenti P (2002). "Clinical practice. Nephropathy in patients with type 2 diabetes". N. Engl. J. Med. 346 (15): 1145–51. doi:10.1056/NEJMcp011773. PMID 11948275.
  2. 2.0 2.1 2.2 Lim A (2014). "Diabetic nephropathy - complications and treatment". Int J Nephrol Renovasc Dis. 7: 361–81. doi:10.2147/IJNRD.S40172. PMC 4206379. PMID 25342915. Vancouver style error: initials (help)